Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials over a Median of 2.3 Years and Up to 4 Years of Treatment.
American journal of clinical dermatology（2025）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined